Denali Therapeutics paid its 3 named executives $12.8M in total in FY2025 (Dec). CEO Ryan J. Watts, Ph.D. was paid $4.8M of that.
Pay$100 in the stock at the end of FY20 → $20
Pay of each named executive
Ryan J. Watts, Ph.D.President and Chief Executive Officer
| FY2025 (Dec) | |||||||
| FY2024 (Dec) | |||||||
| FY2023 (Dec) | |||||||
| FY2022 (Dec) | Not disclosed | ||||||
| FY2021 (Dec) | Not disclosed |
5 years
Alexander O. Schuth, M.D.Chief Operating and Financial Officer and Secretary
| FY2025 (Dec) | |||||||
| FY2024 (Dec) | |||||||
| FY2023 (Dec) | |||||||
| FY2022 (Dec) | Not disclosed | ||||||
| FY2021 (Dec) | Not disclosed |
5 years
Carole Ho, M.D.Chief Medical Officer and Head of Development (until November 14, 2025)
| FY2025 (Dec) | |||||||
| FY2024 (Dec) | |||||||
| FY2023 (Dec) | |||||||
| FY2022 (Dec) | Not disclosed | ||||||
| FY2021 (Dec) | Not disclosed |
5 years
CEO pay against the pay peers
In FY2024 (Dec), the median CEO pay of the 10 peers with pay on file was $14.0M. The CEO of Denali Therapeutics was paid $6.6M, 53% below the median.
- 1CRISPR Therapeutics AG
- 2BridgeBio Pharma
- 3Ionis Pharmaceuticals
- 4Intellia Therapeutics
- 5Cytokinetics
- 6Ultragenyx Pharmaceutical
- 7Vir Biotechnology
- 8Agios Pharmaceuticals
- 9Denali TherapeuticsThis company
- 10Beam Therapeutics
- 11Sarepta Therapeutics
- 12Alector TherapeuticsNot disclosed
- 13Amylyx PharmaceuticalsNot disclosed
- 14Arcus BiosciencesNot disclosed
- 15Axsome TherapeuticsNot disclosed
- 16Cerevel Therapeutics HoldingsNot disclosed
- 17Intra-Cellular TherapiesNot disclosed
- 18Karuna TherapeuticsNot disclosed
- 19Legend Biotech Corp.Not disclosed
- 20Mirati TherapeuticsNot disclosed
- 21Prothena CorporationNot disclosed
- 22REGENXBIONot disclosed
- 23Sage TherapeuticsNot disclosed
- 24VaxcyteNot disclosed
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.